A Phase 4 interventional study of Ulinastatin in Congenital Heart Diseases, sponsored by Techpool Bio-Pharma Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 30 Days to 4 Years. Per ClinicalTrials.gov, last updated 2018-01-17.
Sponsored by Techpool Bio-Pharma Co., Ltd. (part of Shanghai Pharmaceuticals Holding Co., Ltd) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Heart Defects, Congenital with a site in China — 27 open to participants now, 30 under way, none of them phase 3. Heart Defects, Congenital · China.
Among the 79 studies in Heart Defects, Congenital with a site in China, this one is the 10th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2015, is one of 2 in phase 4, and was the 15th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →27 of the 79 studies in Heart Defects, Congenital with a site in China are open now. Recruiting first, the newest first:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages up to 18
Children's Hospital of Fudan University · Sites in China
Ages 0 mo–6 mo
Yan Fuxia · Sites in China
Ages 1 days–3 yrs
Yan Fuxia · Sites in China
Ages 6–12
China National Center for Cardiovascular Diseases · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.
This study: 30 Days to 4 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 5 · Phase 4 2
First in 2000; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 160 across the 41 interventional studies, 1,554 across the 38 observational. Of the 30 that completed or were terminated, 3 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 79 have an industry lead sponsor. The 10 most frequent:
This study is registered under Techpool Bio-Pharma Co., Ltd., one of the names counted as Shanghai Pharmaceuticals Holding Co., Ltd. Under that name alone:
Techpool Bio-Pharma Co., Ltd. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Shanghai Pharmaceuticals Holding Co., Ltd has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Defects, Congenital with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747546Children's Hospital of Fudan UniversityResearch on Circulation Management Strategy Based on Oxygen Metabolism Balance After CHD Surgery | 2026-12-31 |
| NCT06542120Xinhua Hospital, Shanghai Jiao Tong University School of MedicineResearch on Body Voice AI Recognition System for Children's Health Management | 2026-12-31 |
| NCT07115108Children's Hospital of Fudan UniversityEffectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease | 2026-12-31 |
| NCT07854145Shanghai Jiao Tong University School of MedicineStarry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery | 2027-03-31 |
| NCT07375602Xinhua Hospital, Shanghai Jiao Tong University School of MedicineA Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 79 studies in Heart Defects, Congenital with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pediatric patients diagnosed with Complex Congenital Heart Disease ready to accept scheduled open-heart surgery under cardiopulmonary bypass (CPB).
This study uses randomized (centralized randomization) \& controlled design with open label. Eligible subjects will be randomized to receive either study drug (Ulinastatin) or conventional treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
Drug: Ulinastatin
patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.
Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
Also known as: UTI, urinary trypsin inhibitor, bikunin
Dynamic changes of arterial oxygen tension / inspired oxygen fraction (PaO2/FiO2) ratio
Dynamic changes of PaO2/FiO2 ratio will be observed in every 4 hours interval during post-operative ICU stay period
Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days
The time of the PaO2/ FiO2 Ratio ≥300 post surgery
Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days
The proportion of the PaO2/ FiO2 Ratio ≥300 post surgery
Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days
Monitoring arterial hydrogen ion concentration
Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days
Monitoring record of mean blood pressure
Time frame: Intraoperative and Postoperative,an expected average of 6 days
Monitoring record of central venous pressure
Time frame: Intraoperative and Postoperative,an expected average of 6 days
Analysis proinflammatory cytokines Interleukin 1
Time frame: Preoperative and Postoperative on day1 ,day3 and day5
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Apr 2015, a primary completion of Jun 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Urinastatin
Techpool Bio-Pharma Co., Ltd. →